O cular neovascularization is a major cause of irreversible visual loss in several eye diseases, such as proliferative diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, and traumatic corneal injury. [1] [2] [3] The treatments for these diseases are not satisfactory because of the limited understanding of pathogenesis of ocular neovascularization and the poor drug delivery caused by the ocular barriers.
Very low-density lipoprotein receptor (VLDLR) is a membrane receptor originally known to mediate lipid transport. 10 It was reported later that Vldlr −/− mice develop abnormal retinal and subretinal neovascularization. 11, 12 Our previous study has shown that VLDLR deficiency results in Wnt signaling overactivation in the retina, which is responsible for retinal neovascularization, suggesting an inhibitory effect of VLDLR on Wnt signaling and retinal neovascularization. 13 VLDLR belongs to the low-density lipoprotein receptor (LDLR) gene family and is a highly conserved integral membrane protein consisting of a large ectodomain, a single transmembrane domain, and an intracellular domain. 14 The specific functional domain of VLDLR for the interaction with Wnt signaling has not been clearly defined. We hypothesized that the VLDLR N-terminal ectodomain (VLN) is responsible for the inhibitory effect on Wnt signaling, as VLDLR is known to shed VLN into the extracellular space as a soluble peptide. 15 Our previous work has shown that VLN is efficient to block Wnt signaling in vitro, 16 whereas the present study generated nanoparticles capsulated with a plasmid-mediated expression of the soluble VLN with His tag to evaluate the inhibitory effect of VLN on retinal neovascularization and Wnt signaling in vivo. At the same time, nanoparticles expressing the extracellular domain of LDLR (LN) with Myc tag was used as a control because previous studies showed that LDLR knockout does not affect the Wnt signaling pathway or result in neovascular phenotype. 17, 18 Because of the ocular barriers, including the corneal barrier, aqueous barrier, the inner and outer blood-retinal barriers, it is always challenging to deliver large molecules, such as peptides and DNA into the retina. Intravitreal injection is commonly used to deliver genes or proteins into the retina. Because these molecules remain in the eye for only short durations, repetitive injections are needed, which is accompanied by problems, such as cataract, vitreous hemorrhage, and endophthalmitis. Nanoparticles have been applied to improve penetration, controlled and sustained release of drugs, and drug targeting. 19 Several groups have successfully encapsulated naked DNA into biodegradable poly(lactide-co-glycolide acid) nanoparticles for long-term and controlled DNA release. 20, 21 To study the role of VLN in the regulation of Wnt signaling and ocular neovascularization, we encapsulated an expression plasmid of VLN or LN with poly(lactide-co-glycolide acid) polymer to form VLN nanoparticles (VLN-NP)/LN nanoparticles (LN-NP) and evaluated the efficacy of VLN-NP on Wnt3a-induced proliferation, migration, and tube formation of endothelial cells and on ocular neovascularization in ocular neovascularization models, including Vldlr −/− mice, oxygeninduced retinopathy (OIR) model, and alkali burn-induced corneal neovascularization model.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

VLN-NP-Mediated Expression of VLN in Human Retinal Microvascular Endothelial Cells
VLN-NP and LN-NP had a low polydispersity (≤0.2), indicating a narrow particle size distribution, and were negatively charged. The plasmid loading was 1.1% and 0.9% in VLN-NP and LN-NP, respectively (Table in the online-only Data Supplement).
The conditioned serum-free media (3-fold) from primary human retinal microvascular endothelial cells (HRMEC) were harvested 72 hours after the transfection of VLN-NP and LN-NP and concentrated. As shown by Western blot analysis, both of the anti-His-tag and anti-VLN antibodies detected significant amounts of the VLN peptide with the expected molecular weight (100 kDa) in the conditioned medium from the cells transfected with VLN-NP, but not in that from the cells transfected with LN-NP ( Figure 1A ). On the contrary, an anti-Myc-tag antibody detected the expression of LN-Myc only from the cells transfected with LN-NP ( Figure 1A ).
VLN-NP Inhibits HRMEC Growth
Induced by Wnt3a and Small Interfering RNA (siRNA) of VLDLR As shown by MTT assay in HRMEC at various time points after transfection, VLN-NP significantly decreased HRMEC viability at 48 and 72 hours post-transfection, compared with the LN-NP-transfected cells ( Figure 1B) . Furthermore, VLN-NP specifically attenuated Wnt3a-induced HRMEC growth, compared with LN-NP ( Figure 1C ). In addition, the siRNA knockdown of VLDLR resulted in increased numbers of viable HRMEC, which is consistent with a previous study, 22 whereas VLN-NP decreased viable HRMEC, diminishing the effect of the VLDLR siRNA ( Figure 1H ).
VLN-NP Suppresses Wnt3a-Stimulated HRMEC Migration and Tube Formation
HRMEC migration was measured using the transwell chamber assay. As shown in Figure 1D and 1F, Wnt3a-conditioned medium (WCM) stimulated HRMEC migration compared with L cell-conditioned medium. VLN-NP, but not LN-NP, significantly suppressed the endothelial cell migration induced by WCM. Tube formation assay demonstrated that WCM induced tubes formation in HRMEC, whereas VLN-NP significantly suppressed WCM-induced endothelial cell tube formation ( Figure 1E and 1G).
VLN-NP Inhibits Wnt3a-Induced Activation of the Wnt Signaling Pathway In Vitro
To evaluate the modulation of Wnt signaling by VLN in vitro, HRMEC were transfected with VLN-NP or LN-NP. WCM was used to induce Wnt signaling compared with the L cell conditioned medium control. WCM upregulated the levels of phosphorylated LRP6 (p-LRP6), total LRP6 (t-LRP6), n-p-β-catenin, and VEGF, compared with L cell conditioned medium (Figure 2A-2D ). VLN-NP dramatically blocked the increases of LRP6, n-p-β-catenin, and VEGF levels induced by WCM (Figure 2A-2D) .
Transcriptional activity of TCF/β-catenin was measured using TOPFLASH assay. As shown in Figure 2H , WCM increased luciferase activity by almost 100-fold, whereas VLN-NP reduced the activity by 60%, compared with LN-NP ( Figure 2H ), suggesting that VLN-NP directly inhibits Wnt signaling induced by Wnt ligand in endothelial cell.
To determine whether the regulation of VLN on VEGF is through the Wnt signaling pathway, we used a monoclonal antibody Mab2F1, which specifically blocks the ligand-binding site of the Wnt coreceptor LRP6. 23 The results showed that Mab2F1 successfully blocked the VEGF expression induced by WCM ( Figure 2E ) and abolished the inhibitory effect of VLN-NP on Wnt3a-induced VEGF upregulation ( Figure 2E ), suggesting that VLN-NP mediated VEGF suppression acts exclusively through Wnt inhibition. Moreover, an adenovirus expressing a constitutively active mutant of β-catenin (Ad-S37A) was used to induce VEGF overexpression in the absence of Wnt ligand, and the VEGF expression induced by this active mutant of β-catenin was not blocked by VLN-NP as shown at the protein and mRNA levels ( Figure 2F and 2G) . Together, these results suggest that the suppression of VEGF expression by VLN-NP is through inhibiting the Wnt signaling pathway, which occurs at the LRP6 coreceptor level.
VLN-NP Mediates Sustained Expression of VLN in the Retina
To examine the expression and duration of the genes delivered by nanoparticles in the retina, VLN-NP were injected intravitreally (50 μg/eye), with LN-NP as control, and then the retinas were dissected at 1, 2, 3, and 4 weeks (3 mice per time point) after the injection. VLN was detected with an expected molecular weight in the retinas injected with VLN-NP at all of the time points analyzed by Western blotting analysis using the anti-His-tag antibody, but not in the retinas injected with LN-NP ( Figure 3A ). 
VLN-NP Has No Detectable Toxicities to the Structure and Function of the Retina
To detect the possible adverse effect of VLN-NP and LN-NP on visual functions, electroretinography recording was used in the treated eyes and eyes 4 weeks after intravitreal injection of VLN-NP and LN-NP. The amplitudes of A-or B-waves of scotopic and photopic electroretinography in the VLN-NP-treated group were not significantly different among the untreated mice and LN-NP-treated mice ( Figure IA and IB in the online-only Data Supplement).
Possible toxicities of VLN-NP were also evaluated by histological examination. No difference was observed in the number of retinal nuclear layers or thickness of the retina among the mice injected with VLN-NP, LN-NP, and the control ( Figure IC in the online-only Data Supplement).
VLN-NP Inhibits Retinal Neovascularization in Vldlr −/− Mice
As shown by angiography of the flat-mounted whole retinas, Vldlr −/− mice developed small, irregular in shape (coiled or enlarged) intraretinal neovascular blebs throughout the retina, which is consistent with a previous report 24 ( Figure 3B ). The injection of VLN-NP significantly reduced numbers of intraretinal neovascular blebs in Vldlr −/− eyes compared with those with the LN-NP injection ( Figure 3B and 3C) .
BS-1 lectin staining of retinal sections showed decreased vascular density and less abnormal vessels in outer nuclear level of the retina in Vldlr −/− retinas after the VLN-NP injection, compared with those in the retina with LN-NP injection ( Figure 3D ).
VLN-NP Inhibits the Wnt Signaling Pathway in the Retina of Vldlr −/− Mice
Levels of p-LRP6, t-LRP6, n-p-β-catenin, total β-catenin (t-β-catenin), and VEGF were significantly elevated in the eyecups of Vldlr −/− mice with LN-NP injection compared with wild-type mice with LN-NP injection at age of P30, suggesting the activation of Wnt signaling in the Vldlr −/− retinas ( Figure 4A-4D) . A single injection of VLN-NP into Vldlr −/− vitreous at P10 abolished the upregulation of p-LRP6, t-LRP6, n-p-β-catenin, t-β-catenin, and VEGF levels, suggesting that VLN is the functional domain responsible for the inhibition of the Wnt pathway ( Figure 4A-4D ).
VLN-NP Alleviates Ischemia-Induced Retinal Neovascularization in OIR Mice
As shown by fluorescein angiography, severe neovascularization and enlarged nonperfusion area were exhibited in the flat-mounted retinas in the OIR mice treated with LN-NP, whereas the VLN-NP-treated OIR mice displayed alleviated retinal neovascularization and dramatically smaller nonperfusion areas ( Figure 3E and 3F) . Moreover, the VLN-NP-treated OIR group developed significantly fewer preretinal vascular cells, in comparison to LN-NPtreated OIR mice ( Figure 3G and 3H) , supporting an inhibitory effect of VLN-NP on ischemia-induced retinal neovascularization.
VLN-NP Inhibits the Wnt Signaling Pathway in OIR Mice
Our group has previously shown that the Wnt pathway is activated in the retina of OIR model, which contributes to the retinal neovascularization. 23 A single injection VLN-NP attenuated the elevations of p-LRP6, t-LRP6, n-p-β-catenin, t-β-catenin, and VEGF levels in the retina of OIR animals ( Figure 4E-4H) .
We also evaluated the effect of VLN-NP on Wnt signaling activity using the Wnt reporter mice, BAT-gal transgenic mice that express the β-galactosidase gene under the control of a promoter containing TCF/β-catenin-binding sites. As shown by X-gal staining, the retina with OIR showed more intense blue color compared with that of age-matched normal mice, suggesting Wnt pathway activation induced by OIR. The injection of VLN-NP decreased blue color in the retina of OIR mice compared with LN-NP-treated OIR retinas ( Figure 4I ), indicating that VLN-NP downregulates Wnt signaling in the OIR retinas.
VLN-NP Ameliorates Alkali BurnInduced Corneal Neovascularization
Corneal neovascularization was induced with alkali burn in rats, as shown in corneal images, 7 days after the alkali burn. 25 A single topical treatment of VLN-NP (20 μL, 10 mg/ mL) at the procedure day of alkali burn substantially reduced corneal neovascularization induced by alkali burn at day 7 after treatment compared with the same dose of LN-NP ( Figure 5A ). Quantitatively, VLN-NP significantly reduced neovascularization severity in the alkali burn model compared with LN-NP, as measured by corneal neovascularization clock hour ( Figure 5B ) and vascularized area ( Figure 5C ). H&E and CD31 staining of corneal sections showed that the VLN-NP-treated group developed fewer vessels in the cornea with alkali burn compared with untreated and LN-NP-treated groups ( Figure 5D ). 
VLN-NP Suppresses the Wnt Signaling Pathway in the Rat Cornea with Alkali Burn-Induced Neovascularization
As shown in Figure 6 , levels of p-LRP6, t-LRP6, n-p-β-catenin, t-β-catenin, and VEGF in the cornea were significantly elevated in the untreated and LN-NP-treated corneas with alkali burn compared with control without alkali burn. VLN-NP (20 μL, 10 mg/mL) treatment dramatically suppressed the increases of p-LRP6, t-LRP6, n-p-β-catenin, t-β-catenin, and VEGF ( Figure 6A-6D) .
The same procedure of alkali burn was performed in BATgal transgenic mice, and flat-mounted corneas and corneal sections showed more intense blue color, indicative of active Wnt signaling, after X-gal staining in the alkali burn group, without treatment or with LN treatment compared with no burn group. Moreover, significantly less intense blue color was observed in the VLN-NP-treated corneas with alkali burn (Figure 6E ), indicating that VLN-NP inhibited Wnt signaling activity in the cornea with alkali burn-induced neovascularization.
Discussion
Ocular neovascular diseases constitute the most common causes of severe and irreversible vision loss in developed countries. 26 The canonical Wnt signaling pathway plays a vital part in ocular development and diseases, 27 as well as in ischemiainduced retinal neovascularization and laser-induced choroidal neovascularization. 23, 28, 29 Our group reported that VLDLR deficiency results in overactivation of the Wnt signaling pathway and retinal neovascularization, 13 suggesting a potential role of VLDLR as an endogenous inhibitor of Wnt signaling and ocular neovascularization. Recently, our group revealed that the extracellular domain of VLDLR is essential for its inhibition of the Wnt pathway in vitro. 16 However, the potential usage of VLDLR in the treatment of pathological ocular neovascularization diseases has not been established. The present study provided the first in vivo evidence that the soluble extracellular domain of VLDLR is responsible for its inhibition of ocular neovascularization through down-regulating Wnt signaling. Additionally, our data also show that nanoparticle-mediated delivery of VLDLR extracellular peptide is an effective approach to treat ocular diseases in mouse models.
Ocular neovascularization, depending on its location and causation, can have distinct pathogenic mechanisms. However, angiogenic factors, such as VEGF, are commonly involved in almost all types of the ocular neovascularization. Wnt signaling, which is an upstream signaling pathway regulating VEGF, has been shown to play a crucial part in retinal neovascularization formation, and inhibitors of Wnt signaling t-LRP6; B) , non-phosphorylated-β-catenin (n-p-β-catenin) and total β-catenin (t-β-catenin; C), and vascular endothelial growth factor (VEGF; D), which were normalized by β-actin levels. **P<0.01, *P<0.05, n=4. E-H, The retinas were dissected on P17 from LN-NP-treated Normoxia (N+LN), LN-NP-treated OIR (OIR+LN) and VLN-NP-treated OIR (OIR+VLN) groups. Levels of protein were measured by Western blot analysis (E). Densitometry was performed to semiquantify p-LRP6 and t-LRP6 (F), n-p-β-catenin, t-β-catenin (G), and VEGF (H) levels, which were normalized by β-actin levels. **P<0.01, *P<0.05, n=3. I, X-gal staining of retinal sections: VLN-NP or LN-NP was injected intravitreally into BAT-gal mice (50 μg/ eye) with OIR at P12. The retinas were dissected at P17 and sectioned, and β-galactosidase activities were evaluated by X-gal staining (blue). GCL indicates ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; and RPE, retinal pigment epithelium.
have displayed therapeutic potential for retinal neovascularization diseases. 23, 28, 30 This study demonstrates that Wnt signaling is upregulated in all 3 neovascularization models (Figures 4 and 6) , which are consistent with previous studies in Vldlr −/− mice 13, 31 and OIR model. 29, 32 Further, the present study is the first to establish the pathogenic role of Wnt signaling in corneal neovascularization. Although β-catenin was reported to be upregulated in the neovascularized cornea after alkali burn, 30 it was not clear whether the Wnt pathway was activated because β-catenin has multiple functions in addition to participating in Wnt signaling cascade, such as modulating cellular adhesion and cytoskeleton. 33 The present study evaluated the Wnt pathway activity at multiple levels, including phosphorylation of a Wnt coreceptor, LRP6; upregulation of VEGF, a direct target gene of β-catenin; and transcriptional activity of β-catenin in the corneas ( Figure 6 ). All of these assays showed that Wnt signaling was activated in the neovascularized cornea after alkali burn, thus providing further evidence for a key pathogenic role of Wnt signaling in ocular neovascularization. In addition, we also measured the expression of transcription factor TCF in HRMEC. The TCF mRNA was not altered with the treatment of WCM or VLN-NP ( Figure III in the online-only Data Supplement). The functional suppression of TCF activity by VLN is supported by our results from TOPFLASH assay ( Figure 2H) , showing that VLN suppressed Wnt3a-induced TOPFLASH activity, indicative of TCF transcriptional activity. Therefore, the transcriptional function of TCF, rather than its expression level, is relevant to Wnt signaling activity and VLN suppression.
LRP6 and VLDLR both belong to the LDLR family and share significant amino acid sequence identity in their extracellular domains. 34 It has been established that the extracellular domain of LRP6 is the essential binding domain for Wnt ligands and some Wnt signaling inhibitors, such as Dickkopf1, 35, 36 and also required for homodimerization of LRP6 to initialize Wnt signaling. 37 As the extracellular domain of VLDLR can be shed into the extracellular space, 15 we hypothesized that the soluble extracellular domain of VLDLR may function as a soluble cytokine and confer some physiological or pathological functions distinct from its membrane form. Based on the hypothesis, our group dived into the structural basis for the inhibitory effect of VLDLR on Wnt signaling and found that VLN is essential for the inhibition of Wnt signaling. 16 Here we generated a nanoparticle-encapsulated extracellular domain of VLDLR, termed as VLN-NP. Our results show that VLN is sufficient to inhibit Wnt3a-induced HRMEC growth, migration, and tube formation ( Figure 1B-1G) . Moreover, it was reported that knockdown of VLDLR by siRNA enhanced endothelial cell viability, migration, and tube formation. 22 Our data show that VLN-NP inhibits HRMEC growth induced by the VLDLR siRNA ( Figure 1H ), suggesting that the ectodomain of VLDLR is sufficient to constitute the Wnt-inhibiting function of VLDLR in regulation of Wnt signaling. Three animal models all demonstrated that VLN-NP ameliorate ocular neovascularization and suppress Wnt signaling as shown at the receptor level (LRP6), transcription factor level (β-catenin), and target gene level (VEGF) in vivo. Our data showed that a specific blocker of LRP6 attenuated the VEGF expression induced by WCM, similar to the effect of VLN-NP ( Figure 2E ). Further, VLN-NP did not decrease VEGF expression induced by a constitutively active mutant of β-catenin (Ad-S37A), which activates Wnt target genes down-stream of LRP6 in HRMEC ( Figure 2F and 2G) . These results support that the inhibition of VEGF by VLN is achieved through suppressing Wnt signaling at the coreceptor LRP6 level. Our recent publication demonstrated that VLDLR inhibits Wnt signaling through the formation of a heterodimer with LRP6. 16 This heterodimerization blocks the binding of Wnt ligand and the coreceptor LRP6, which is an essential step in the activation of Wnt signaling. The heterodimerization also reduces LRP6 levels on the cell surface by accelerating its internalization and turnover of LRP6, 16 which explains the reduction of total LRP6 in VLN-NP-treated group and nonsignificant changes of the p-LRP6/t-LRP6 ratios in this study. Here, our data showed that the mRNA levels of LRP6 were not changed The delivery of macromolecules, such as DNA and protein to ocular tissues, especially the posterior segment, is challenging because of the existence of structural barriers. Therefore, the development of nano-sized carriers may represent a promising approach in ocular drug delivery. 38 Although the nanoparticles formulated using poly(lactide-co-glycolide acid) polymers have not been widely used in clinic, they are being extensively used in research because of their sustained release characteristics, biodegradability, biocompatibility, and ability to protect DNA from degradation. 39 Our data showed that VLN-NP mediated substantial and sustained VLN expression in cultured cells and in the retina for ≥4 weeks after a single injection, confirming effective internalization of the nanoparticles, and that the cargo protein VLN is expressed and released into the extracellular space.
In conclusion, this study suggests that the Wnt signaling pathway plays an important pathogenic role in corneal and retinal neovascularization; nanoparticle-mediated delivery of soluble VLN has therapeutic potential for ocular neovascularization -LRP6; B) , non-phosphorylated-β-catenin (n-p-β-catenin) and total β-catenin (t-β-catenin; C), and vascular endothelial growth factor (VEGF; D) levels by densitometry and normalized by β-actin levels. **P<0.01, *P<0.05, n=3. E, X-gal staining of the whole corneas and corneal sections. Corneas from BAT-gal mice were isolated at Day 7 after the alkali burn and fixed. Corneal flat-mount and frozen sections were stained with X-gal to evaluate the expression of β-galactosidase reporter (blue). Endo indicates endothelium; Epi, epithelium; and S, stroma.
diseases and likely through the inhibition of Wnt signaling. However, there are still some unsolved questions that warrant further studies in the future. Previous study showed that Vldlr −/− retinas and downregulation of VLDLR by siRNA resulted in upregulation of LRP6 expression at both the protein and mRNA levels, 13 whereas our data indicate that the Wnt signaling pathway and VLN does not affect LRP6 mRNA level. It is possible that VLDLR regulates LRP6 expression at different levels, depending on cell types, duration of the treatment, and types of the treatments. The present study focuses on the mechanism that VLN regulates LRP6 at the post-translational level, and further study needs to be performed to demonstrate the molecular mechanism by which VLDLR modulates Wnt signaling through downregulating LRP6 at different levels. In addition, although nanoparticle significantly reduces the frequency of injection, there may be still associated risks because of the characteristics of intravitreous injection. Better drug administration remains to be explored. Nevertheless, VLN-NP represents a promising strategy to treat ocular neovascularization, providing an encouraging perspective for clinic usage.
